Editas Medicine (EDIT)
Earlier this month, we brought you attention to CRISPR Therapeutics (CRSP), as it traded at $58.58 a share. It’s now up to $68.55. Now, as we wait on a final decision from the US FDA in early December, the CRSP stock could move even higher on anticipatory momentum.
Better, as noted by Seeking Alpha, “The companies believe the addressable patient pool for exa-cel treatment will number ~20,000. If we multiply that by $2m, the mooted list price, we have a market opportunity of $40bn, and if we multiply that by 40%, CRISPR Therapeutics’ share of revenues, we get to $16bn.”
While we still like CRSP, we also like Editas Medicine (EDIT), which also has a strong December catalyst. In fact, “The Company will share clinical data updates from the RUBY trial for severe sickle cell disease (SCD) and the EdiTHAL trial for transfusion-dependent beta thalassemia (TDT) in a company-sponsored webinar and in a poster at the American Society of Hematology (ASH) annual meeting on Monday, December 11,” as noted in a recent company press release.
Ian Cooper is an experienced trader who uses a combination of technical, fundamental, and news analysis to help individual investors grow their wealth. Ian’s Premium Options Strategies